On April 23, 2026, the FDA granted accelerated approval to Otarmeni (lunsotogene parvec-cwha), the first gene therapy for genetic hearing loss. The treatment targets children and adults with severe-to-profound sensorineural hearing loss caused by mutations in both copies of the OTOF gene. Regeneron Pharmaceuticals announced it will provide Otarmeni at no cost in the United States.

This is the first FDA-approved gene therapy to restore a neurosensory function to normal levels.

What OTOF Mutations Cause

The OTOF gene produces otoferlin, a protein critical for transmitting sound signals from inner hair cells to the auditory nerve. When both copies of the gene are defective (biallelic mutations), children are typically born with severe-to-profound hearing loss. The condition affects roughly 1 to 3% of children with congenital hearing loss, though many cases go undiagnosed without genetic testing.

Kids with OTOF-related hearing loss often develop language and communication skills through sign language, cochlear implants, or hearing aids. But cochlear implants don't work for everyone, and hearing aids provide limited benefit when hearing loss exceeds 90 decibels.

How Otarmeni Works

Otarmeni delivers a functional copy of the OTOF gene directly into the inner ear using a dual adeno-associated virus (AAV) vector. A surgeon injects the therapy into the cochlea through a catheter in a single-dose procedure per ear.

The gene therapy restores otoferlin production in inner hair cells, which allows auditory signals to reach the brain. It doesn't cure deafness across all causes, it targets this specific genetic pathway.

What the Clinical Trial Showed

In the CHORD trial, 20 pediatric patients (ages 10 months to 16 years) with biallelic OTOF mutations received Otarmeni. Eighty percent of participants met the primary endpoint: achieving hearing sensitivity of 70 decibels or better on pure tone audiometry at 24 weeks.

With longer follow-up, 42% of treated patients achieved normal hearing, including the ability to hear whispers. The FDA granted approval under its National Priority Voucher program, which accelerates review for therapies addressing urgent public health needs.

Safety data showed the treatment was generally well-tolerated. The most common adverse events were related to the surgical procedure itself, not the gene therapy.

What This Means for Families

Many families with deaf or hard-of-hearing children never receive a genetic diagnosis. Audiologists often attribute hearing loss to prematurity, infection, or unknown causes. Without genetic testing, families don't know whether their child has an OTOF mutation, and therefore don't know whether they might benefit from Otarmeni.

The fact that Regeneron is providing the therapy at no cost eliminates a major barrier. Gene therapies typically cost hundreds of thousands of dollars. Families who qualify won't face insurance denials, prior authorizations, or out-of-pocket costs.

Eligibility is narrow: the patient must have severe-to-profound sensorineural hearing loss (greater than 90 decibels at any frequency) and confirmed biallelic OTOF mutations through molecular testing.

What Families Can Do Now

If your child has unexplained severe-to-profound sensorineural hearing loss, ask your audiologist about genetic testing for OTOF mutations. Testing typically requires a blood or saliva sample and is often covered by insurance when there's a clinical indication.

If genetic testing confirms biallelic OTOF mutations, contact your child's ENT or audiologist to discuss whether Otarmeni is appropriate. The treatment is administered surgically, so it requires a medical evaluation to determine candidacy.

For families whose children already use cochlear implants or hearing aids, Otarmeni may still be an option depending on the child's age and hearing thresholds. Discuss with your care team whether gene therapy could improve outcomes beyond what current devices provide.

Regeneron has not yet published detailed information about how families can access the free treatment program, but that guidance is expected in the coming weeks.

Timeline

• April 23, 2026: FDA grants accelerated approval to Otarmeni
• Ongoing: Regeneron begins rollout of no-cost access program in the U.S.
• Next steps: Families with confirmed OTOF mutations should contact their care teams to discuss eligibility and timing

The approval marks a shift in how genetic hearing loss may be treated. For families who've been told "there's nothing we can do," this changes the conversation.